Zobrazeno 1 - 10
of 36
pro vyhledávání: '"C. H. Kleinbloesem"'
Autor:
A. Högemann, J. F. W. Hoogkamer, C. H. Kleinbloesem, A. Nokhodian, M. J. A. Ouwerkerk, E. Weidekamm, Wilhelm Kirch
Publikováno v:
European Journal of Clinical Pharmacology. 54:341-345
Objective: The influence of liver disease on the pharmacokinetics of candesartan, a long-acting selective AT1 subtype angiotensin II receptor antagonist was studied. Methods: Twelve healthy subjects and 12 patients with mild to moderate liver impairm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fe3fe5dc47622d2490eea52c072dd6a
https://doi.org/10.1007/s002280050471
https://doi.org/10.1007/s002280050471
Autor:
Ulrich Feifel, Arend‐Jan J Woittiez, Gustav G Belz, Peter van Brummelen, Horst A. Welker, Rita Schmitt, Hans Pozenel, Wilhelm Kirch, V Schroeter, Atef Halabi, C H Kleinbloesem
Publikováno v:
Clinical Pharmacology and Therapeutics. 52:314-323
The tolerability and hemodynamic and humoral effects of the structurally novel calcium antagonist Ro 40-5967 were investigated in 64 patients with hypertension. In a double-blind, placebo-controlled study, ascending oral doses of 50, 100, 150, or 200
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ba1ad71ab0b7b815c010f57ea0083dd
https://doi.org/10.1038/clpt.1992.147
https://doi.org/10.1038/clpt.1992.147
Publikováno v:
European Journal of Clinical Pharmacology. 41:307-311
In a double blind study 8 patients with uncomplicated essential hypertension received in random order single oral doses of placebo and 10, 30 and 80 mg Ro 23-6152, a novel calcium entry blocker, on 4 different days. Patients were assessed 15 min befo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::364917a6830046eafda00a7d26beb1d7
https://doi.org/10.1007/bf00314957
https://doi.org/10.1007/bf00314957
Autor:
C H Kleinbloesem, Fridolin Hefti, Jean-Paul Clozel, Rita Schmitt, Robert Tudor, Bernhard Schläppi, Herwig Eggers, Horst A. Welker, Wolfgang Osterrieder
Publikováno v:
Cardiovascular Drug Reviews. 9:4-17
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d9810dd2b3e49b45c51d0818e8d4919
https://doi.org/10.1111/j.1527-3466.1991.tb00539.x
https://doi.org/10.1111/j.1527-3466.1991.tb00539.x
Autor:
C. H. Kleinbloesem, J. F. W. Hoogkamer
Publikováno v:
Drugs. 49:346-348
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62f8b9269c0114ee3ce34d933466c1b8
https://doi.org/10.2165/00003495-199500492-00094
https://doi.org/10.2165/00003495-199500492-00094
Autor:
G. Lankhaar, Wilhelm Kirch, C. H. Kleinbloesem, A. Nokhodian, J. F. W. Hoogkamer, W. Ungethüm, M. J. A. Ouwerkerk
Publikováno v:
European journal of clinical pharmacology. 54(1)
An open study on the single dose and steady-state pharmacokinetics of imidapril, a novel prodrug-type angiotensin-converting enzyme (ACE) inhibitor, and its active metabolite imidaprilat was conducted in eight patients with moderate chronic renal fai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::969b08b2bca90e8bd932e544b25cbfd4
https://pubmed.ncbi.nlm.nih.gov/9591932
https://pubmed.ncbi.nlm.nih.gov/9591932
Publikováno v:
Arzneimittel-Forschung. 46(10)
The bioequivalence and relative bioavailability of a new sustained release formulation of diltiazem (120 mg, Diltiazem-Mepha 120 retard, CAS 33286-22-5) in comparison with a 120 mg reference formulation was investigated in a randomised 2-way cross-ov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::68de817714f4e7f36b0fad526297a2b3
https://pubmed.ncbi.nlm.nih.gov/8931888
https://pubmed.ncbi.nlm.nih.gov/8931888
Publikováno v:
Arzneimittel-Forschung. 45(10)
The absorption, pharmacokinetics and bioavailability of ibuprofen (CAS 15687-27-1) were investigated for an ibuprofen gel preparation (ibugel) for percutaneous application, and compared to a standard oral ibuprofen tablet preparation. The monocentric
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::66b2d8cb40086193e77349238286bd5a
https://pubmed.ncbi.nlm.nih.gov/8595072
https://pubmed.ncbi.nlm.nih.gov/8595072
Autor:
R, Herrmann, C H, Kleinbloesem
Publikováno v:
Arzneimittel-Forschung. 45(8)
An investigation on the bioavailability of a new tablet with 160 mg sotalol hydrochloride (CAS 959-24-0, Rentibloc 160), was performed in a two-way cross-over study with 16 volunteers. The relative bioavailability with respect to a reference preparat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4f7f72fba6bb9c46585721a720a3103d
https://pubmed.ncbi.nlm.nih.gov/7575745
https://pubmed.ncbi.nlm.nih.gov/7575745
Autor:
R, Herrmann, C H, Kleinbloesem
Publikováno v:
Arzneimittel-Forschung. 44(5)
Bioequivalence of a New Sotalol Hydrochloride Tablet Formulation Compared with a Standard Preparation An investigation on the bioavailability of a new tablet with 80 mg sotalol hydrochloride (Rentibloc mite, CAS 959-24-0) was performed in a two-way c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::48120cebee6d9ded54b044f69291c717
https://pubmed.ncbi.nlm.nih.gov/8024627
https://pubmed.ncbi.nlm.nih.gov/8024627